000			02130 a2200577 4500
005			20250517131504.0
264		0	_c20170814
008			201708s 0 0 eng d
022			_a1468-2060
024	7		_a10.1136/annrheumdis-2016-210105 _2doi
040			_aNLM _beng _cNLM
100	1		_aKavanaugh, A
245	0	0	_aFilgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). _h[electronic resource]
260			_bAnnals of the rheumatic diseases _cJun 2017
300			_a1009-1019 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAdministration, Oral
650	0	4	_aAntirheumatic Agents _xtherapeutic use
650	0	4	_aArthritis, Rheumatoid _xblood
650	0	4	_aC-Reactive Protein _xmetabolism
650	0	4	_aDisability Evaluation
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aHemoglobins _xmetabolism
650	0	4	_aHumans
650	0	4	_aInfections _xchemically induced
650	0	4	_aJanus Kinase 1 _xantagonists & inhibitors
650	0	4	_aMale
650	0	4	_aMethotrexate _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aRetreatment
650	0	4	_aSeverity of Illness Index
650	0	4	_aSurveys and Questionnaires
650	0	4	_aTreatment Outcome
650	0	4	_aTriazoles _xadministration & dosage
700	1		_aKremer, J
700	1		_aPonce, L
700	1		_aCseuz, R
700	1		_aReshetko, O V
700	1		_aStanislavchuk, M
700	1		_aGreenwald, M
700	1		_aVan der Aa, A
700	1		_aVanhoutte, F
700	1		_aTasset, C
700	1		_aHarrison, P
773	0		_tAnnals of the rheumatic diseases _gvol. 76 _gno. 6 _gp. 1009-1019
856	4	0	_uhttps://doi.org/10.1136/annrheumdis-2016-210105 _zAvailable from publisher's website
999			_c26712837 _d26712837